Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$981.5MCash, Jun 2026
26moCash Runway (est.)
+39%Share Count, 1 Year
Follow VRDN by emailGet an email when VRDN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VRDN, unsubscribe in one click. Privacy
📣 What VRDN Says Is Next
2H 2026 · “VRDN-008: phase 1 healthy volunteer data expected in 2H 2026”
Company press release, Aug 6, 2026 · SEC filing
Q4 2026 · “Viridian plans to submit an Investigational New Drug (IND) application in Q4 2026 and expects to develop this program in TED and Graves’ disease.”
Company press release, Aug 6, 2026 · SEC filing
Q4 2026 · “TSHR program: IND submission anticipated in Q4 2026”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
VRDN reported $981.5M in cash and short-term investments (as of Jun 30, 2026) and used about $113.4M/quarter in operations, an estimated runway of 26 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:39 · Moderate
Cash runway 26 months
ATM program on file since Sep 2025 +15
Shelf registration (S-3ASR, Sep 2025) +10
Share count +39% in a year +14
Recent financing filings on SEC EDGAR:
May 8, 2026 · Convertible notes offering, $125M · 424B5
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRDN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.